Antigen-presenting cells (APCs) occupy diverse anatomical tissues, but their tissuerestricted homeostasis remains poorly understood. Here, working with mouse models of inflammation, we found that mechanistic target of rapamycin (mTOR)-dependent metabolic adaptation was required at discrete locations. mTOR was dispensable for dendritic cell (DC) homeostasis in secondary lymphoid tissues but necessary to regulate cellular metabolism and accumulation of CD103 + DCs and alveolar macrophages in lung. Moreover, while numbers of mTOR-deficient lung CD11b + DCs were not changed, they were metabolically reprogrammed to skew allergic inflammation from eosinophilic T helper cell 2 (T H 2) to neutrophilic T H 17 polarity. The mechanism for this change was independent of translational control but dependent on inflammatory DCs, which produced interleukin-23 and increased fatty acid oxidation. mTOR therefore mediates metabolic adaptation of APCs in distinct tissues, influencing the immunological character of allergic inflammation.
A fundamental property of the immune system is its ability to sense pathogens through pattern recognition receptors. Emerging evidence demonstrates that immune cells also sense environmental perturbations that induce cellular stress and metabolic changes (1, 2) . However, the mechanisms underlying such environmental sensing are poorly understood. The amino acid sensor GCN2 plays a role in programming dendritic cells (DCs) to respond to viral vaccination (3, 4) and controls intestinal inflammation by suppressing inflammasome activation in the gut (5) . In addition to GCN2, the mechanistic target of rapamycin (mTOR), a central orchestrator of cellular metabolism, regulates DC function (6) . mTOR functions in two supramolecular complexes termed mTORC1 and mTORC2, engaged to differing degrees by diverse stimuli, including Toll-like receptor signaling, growth factors, and nutrient availability. mTOR signaling affects diverse downstream cellular processes, including cell cycle progression, cell growth, differentiation, survival, and metabolism (7) . Although mTOR is required for effector T cell expansion (8) and germinal center B cell responses (9) , it restrains T memory generation (10) . Within DCs, mTOR promotes type I interferon production by plasmacytoid DCs (11, 12) but limits proinflammatory cytokine production by classical DCs (13) . Moreover, mTOR promotes steady-state DC accumulation downstream of homeostatic cytokine signaling (14) (15) (16) ). The precise functions of mTOR have been proposed to be DC subset dependent (17) , but the consequence of mTOR signaling in DCs and the effect on immune responses in vivo are poorly understood.
Results

mTOR promotes lung APC homeostasis in vivo
We bred mice bearing floxed Mtor with a CD11c-Cre deleter strain (mTOR DAPC ), resulting in specific genetic ablation, reduced protein abundance, and loss of mTOR pathway activity in CD11c + cells ( fig. S1, A to D) . mTOR inhibition augments DC proinflammatory cytokine production (13, 17 (18, 19) , both of which activate mTOR (14) . In addition, antigen-presenting cells (APCs) occupy distinct microenvironments where mTOR may exhibit site-specific functions (15, 20) . mTOR DAPC ablation did not exert global effects on APCs but instead revealed defects in APC accumulation at specific anatomical sites. There was negligible requirement for cell-intrinsic mTOR in most tissues examined; however, splenic CD11b + DCs were modestly reduced and there was a skewed ratio of CD103 + to CD11b + DCs in thymus ( fig. S2 ). We also confirmed a substantial reduction in Langerhans cell frequency (15) (fig. S3 ). However, the most striking effect of mTOR DAPC deletion was observed in the lung. Here, CD103
+ DC and CD11c + alveolar macrophage (AM) populations were significantly reduced (Fig. 1A) . Mixed BM chimeras showed that homeostatic defects were cell intrinsic and additionally revealed a minor impairment in CD11b + lung DC accumulation (Fig. 1B) 1D ) due to cell-intrinsic defects in accumulation (Fig. 1E) . Thus, mTOR plays a central, cell-intrinsic role in APC homeostatic accumulation and subset composition in the lung.
Steady-state DC homeostasis depends on cell development, proliferation, migration, and death rates. Ablation or inhibition of mTOR increased death rates of lung APCs ( Fig. 2A and fig. S6 , A and B), whereas precursor frequency, proliferation rates, and migration were unaffected ( fig. S6 , C to G). There was no evidence that GM-CSF, M-CSF, or Flt3L expression was perturbed in mTOR APCs in the lung display a distinctive mTOR-dependent metabolic signature
The pronounced phenotype of APCs in mTOR DAPC lung relative to other tissues was striking, particularly considering that development of CD103 + DCs in both lung and other tissues is regulated by the common transcription factor Batf3 (23). We hypothesized that the lung microenvironment may imprint a distinctive metabolic phenotype with heightened sensitivity to mTOR ablation. To investigate this, comprehensive metabolic profiling was performed on lung and splenic APCs from WT mice. Lung and spleen APCs were metabolically distinct (Fig. 2B) , exhibiting differences in amino acid and nucleic acid metabolic intermediates ( fig. S8, A and B ), which were also reflected within observed transcriptional signatures ( fig. S8 , C and D). We next examined mTOR DAPC metabolomes, and the degree of metabolic perturbation in mTOR-deficient APC subsets correlated with the extent of their homeostatic disruption (Fig. 2C) . Despite the skewing in the phenotypic composition of the lung CD11b + DCs (Fig. 1D) , there was a minor perturbation in the metabolome (Fig. 2C) . Pathway analysis of differentially abundant metabolites revealed that several amino acid metabolic pathways were disrupted in mTOR DAPC APCs (Fig. 2, D and E). mTOR DAPC AMs also exhibited alterations in lipid metabolite expression and corresponding changes in expression of the sterol regulatory binding protein (Srebp1/2) target genes (24) (fig. S9 ). Srebp1 orchestrates lipid anabolism and is a downstream target of mTOR, which directly links mTOR deficiency and metabolic perturbations in lung APCs (25, 26) . To test this experimentally, we administered the Srebp1/2 inhibitor fatostatin, which substantially decreased AM frequency, a phenotype that was recapitulated by rapamycin treatment ( fig. S10A ). However, CD103 + DCs remained unaltered by either inhibitor, suggesting that inhibitor administration was insufficient to entirely phenocopy mTOR DAPC mice, or that the Srebp pathways are not critical for CD103 DC survival. Finally, we investigated the role of another mTOR target, the glycolytic regulator Hif1a, observing that lung APC homeostasis was independent of Hif1a (fig. S10B). Thus, lung APCs have distinct mTOR-dependent metabolic signatures, and there appears to be a direct link between mTOR and Srebp-dependent lipid metabolism in AMs.
Ablation of mTOR in APCs reprograms allergic inflammation in the lung
We next investigated whether lung immunity was functionally affected in mTOR DAPC mice. Mice were intranasally challenged with house dust mite (HDM) allergen, which is an established murine model for asthma (27, 28) (Fig. 3A) . Despite reduced frequencies of select lung APC subsets, humoral responses in mTOR DAPC mice were unexpectedly increased ( Fig. 3B and fig. S11A ). Surprisingly, we observed a striking reduction in 2 of 8 enhance neutrophils. Neutrophilia occurs in~50% of human asthma cases, correlating with steroid resistance and worsening prognosis (29, 30) . Remarkably, we observed pronounced neutrophilia in mTOR DAPC lung and BAL (Fig. 3D) −/− mice, which lack a transcription factor required for CD103 + DC development (Fig. 4B) . However, Batf3 −/− mice did not exhibit differential severity or modality of inflammation (Fig. 4 , C to E), suggesting that impaired development of CD103 + DC was not necessary to promote neutrophilic inflammation.
AMs reside in the lung alveolar lumen and play a primary role in phagocytizing particulates and turning over lung surfactant. Defects in AM result in accumulated lung surfactant protein, termed pulmonary alveolar proteinosis (PAP) (32) . Histological analysis of naïve mTOR DAPC lung showed airspace filling by eosinophilic material (Fig. 5A), elevated mucus (Fig. 5B) accumulation of lung surfactant protein (Fig.  5C ), and increased debris and "foamy" macrophages in BAL (Fig. 5D ). Increased proteinaceous matter was also evident in lung preparations by flow cytometry (Fig. 5E ). These data represent hallmark features of PAP disease (33), representing a first link between mTOR signaling and PAP. We next determined whether functional loss of AMs also contributes to neutrophilic lung inflammation. Using a previously described protocol (34), we observed~75% depletion of AMs 3 days after a single intratracheal (i.t.) dose of clodronate liposomes but not control liposomes (Fig. 5F ). After HDM challenge, humoral immunity was enhanced when AMs were depleted, in concordance with the phenotype observed in mTOR DAPC mice (Fig. 5G) . However, T H 17 polarization and neutrophilia were not present under these conditions (Fig. 5, H lung DCs differentially responded to allergy. HDM was instilled i.t., and mice were examined after 3 days. mTOR DAPC CD11b + migratory DCs accumulated with enhanced frequency in mediastinal lymph node (MedLN) (fig. S17A) , and cellular inflammation was enhanced in the lung (fig. S17B) (28) and were elevated in mTOR DAPC mice (Fig.  6A) . Lung inflammatory DCs were confirmed to be distinct from lung-resident interstitial macrophages, AMs, and classical DCs. They exhibited lower expression of F4/80, higher expression of MHC-II and CD11c compared to interstitial macrophages ( fig. S18C) , lower Siglec-F expression than AMs ( fig. S18D) (Fig. 6B and fig. S19 ).
Given the observed mTOR-dependent metabolic phenotypes in steady-state lung APCs, we asked whether there was a metabolic basis for the T H 17 allergic phenotype. Despite minimal differences between resting classical CD11b + DCs in lungs of WT and mTOR DAPC mice, there was a striking perturbation in the metabolome of inflammatory DCs ( fig. S20 ). In addition to differences in amino acid metabolism found in other DC subsets, we detected elevated fatty acid (FA) metabolites (Fig. 6C) . mTOR inhibition in BMDCs can enhance fatty acid oxidation (FAO) and thereby regulate DC life-span/cytokine expression profiles (39, 40) . However, a physiological role for this mechanism in primary DCs has not been described. To directly investigate whether elevated FAO underlies enhanced inflammatory DC activity, we treated mTOR DAPC mice with etomoxir, an inhibitor of the rate-limiting FAO enzyme carnitine palmitoyltransferase 1 (Cpt1) (41) . Etomoxir significantly reduced the activation phenotype of mTOR DAPC inflammatory DCs without affecting WT (Fig. 6D) and also reduced T H 17 polarization in mTOR DAPC lung (Fig. 6E ). These observations are consistent with a model in which mTOR deletion in inflammatory lung DCs increases FAO to promote T H 17-polarizing activity.
Finally, we investigated whether dysregulated cytokine production by inflammatory DCs influences allergic polarity. The proinflammatory cytokines IL-6 and IL-1b function upstream of IL-23 to promote a T H 17-polarizing cascade. Analysis of CD11b + DCs in lung and MedLN 3 days after administration of HDM revealed evidence of elevated IL-12/23p40, IL-6, and IL-1b, all of which are associated with T H 17 polarization and neutrophilia ( fig. S21, A and B) (29) . IL-23 neutralization reverted lung neutrophilia toward an eosinophilic phenotype (Fig. 6F) , concomitant with restoration in T cells of T H 2 polarity ( fig.  S21C ), identifying this cytokine as a key immunological player in mTOR DAPC -dependent neutrophilic inflammation.
Discussion
Here, we demonstrate a striking heterogeneity in the metabolic profiles of APCs in distinct tissues and reveal a key role for mTOR in programming the homeostasis and function of APC subsets in the lung. In the steady state, mTOR DAPC mice exhibited tissue-dependent phenotypes with reduced numbers of AMs and CD103 DCs in the lung and skin, but not elsewhere, unlike more global phenotypes observed when GM-CSF or Flt3l signaling is impaired (14, 18, 38) . These effects were mediated by Raptor-dependent mTORC1 signaling but, surprisingly, were independent of translational regulation of mRNA, the canonical signaling pathway downstream of mTOR. Instead, our data reveal a role for Srebp1/ 2 signaling downstream of mTOR in homeostasis of lung APCs in the steady state ( fig. S10 ). The selective effects of mTOR deficiency in CD103 DCs in the lung and skin were surprising, because the development of this DC subset in diverse tissues is controlled by the transcription factor Batf3. Thus, these results suggest that the homeostasis of DCs in tissues is orchestrated by the superimposition of a metabolic program on the transcriptional network that regulates development. In addition to these effects in the steady state, mTOR deficiency also altered the character of allergic inflammation induced by lung CD11b + DCs, skewing it toward the T H 17/neutrophilic phenotype. This phenotype closely parallels aspects of human disease, in which neutrophilia associates with higher clinical severity and worse prognosis in asthma (29) . Interestingly, the allergic phenotype observed in mTOR DAPC mice was associated with elevated immunoglobulin E (IgE). Such elevation in serum IgE is also observed in neutrophilic asthma patients (42) and can be enhanced by IL-23 (43) , which is consistent with the IL-23 dependence of the mTOR DAPC neutrophilic inflammation phenotype. In normal circumstances, mTOR signaling in activated BMDCs suppresses oxidative phosphorylation and is in part responsible for a switch to glycolytic metabolism, which rapidly depletes intracellular energy reserves and associates with a shortened cellular life span (1) . In contrast, mTOR inhibition allows BMDCs to supply their energetic demands through a combination of glycolysis and FAO, increasing cell survival and proinflammatory phenotypes (39 
